Breast Cancer
Conditions
Interventions
Observation group:None
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years at the index date (no upper limit) 2.HER2 overexpressing/amplified breast cancer Stage I-III, regardless of HR status 3.Received >=1 dose of neratinib as extended adjuvant treatment and ended treatment before 30th April 2024
Exclusion criteria
Exclusion criteria: 1.Patient was complicated with other primary cancer before the index date; 2.Patient participated in a clinical trial; 3.Concurrent or another previous malignancy within 2 years of study entry; 4.Presence of any contraindication with regard to the neratinib treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient demographics at neratinib initiation;Clinical characteristics at neratinib initiation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment patterns of breast cancer;Neratinib treatment patterns;The safety of neratinib treatment;Neratinib treatment-related diarrhea; | — |
Countries
China
Contacts
Public ContactBinghe Xu
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed